MAR 20, 2015 04:08 PM PDT

World-First Cancer Drugs Could Work in Larger Group of Patients

A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumors with another type of genetic fault, a new study suggests.

Scientists at The Institute of Cancer Research, London, found that errors in a gene called CBLC leave cancer cells vulnerable to PARP inhibitor drugs. Around 2 percent of all tumors have defects in CBLC.

The study, which was carried out in collaboration with colleagues in Denmark and the Czech Republic, was funded in the UK by the European Union, and was published today in the journal Oncotarget.

Olaparib, a PARP inhibitor, became the first cancer drug targeted at an inherited genetic fault to reach the market when it was approved in December for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. Its development was underpinned by research at the ICR.

Using an approach known as RNA interference screening - which ‘silences' genes to analyse their function - researchers systematically tested which of the 25,000 genes in the human genome affected the response of cancer cells to olaparib.

The ICR team found that cancer cells with a defect in the CBLC gene were as sensitive to the drug as those with a faulty BRCA2 gene.

By analysing the molecular processes that the CBLC gene controls, researchers found that it normally allows cells to repair damaged DNA by fixing broken DNA strands back together.

This finding indicates that a flaw in DNA repair mechanisms explains the sensitivity of CBLC-defective cancer cells to PARP inhibitors - which knock out the action of another DNA repair mechanism.

DNA repair is often disrupted in cancer cells, which sacrifice genetic stability as they gain mutations that allow them to divide uncontrollably. These cancer cells may be particularly vulnerable to drugs to block DNA repair proteins, since they may lack any alternative functioning repair systems to fall back on.

Study co-leader Dr Chris Lord, Team Leader in Gene Function at the ICR, said: "Our study has found that defects in a rather poorly studied DNA repair gene called CBLC
seem to greatly increase sensitivity to olaparib, a PARP inhibitor which is currently licensed only for BRCA-mutated cancer.

"PARP inhibitors are an exciting new class of cancer drug. Understanding why different types of tumor cells respond to PARP inhibitors will play a critical part in making sure these new drugs are used in the most effective way."

Professor Paul Workman, Chief Executive of the ICR, said: "The development of PARP inhibitors is a UK success story, with collaboration between ICR academics, companies, charities and the NHS leading to trials in BRCA-mutated cancers and the licensing of olaparib only a few months ago.

"This new study adds to evidence that PARP inhibitors can be effective in a broader group of patients than those with BRCA mutations, and could lead to them being used more widely in patients with other kinds of faults in DNA repair."

Source: Institute of Cancer Research
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 05, 2018
JUN 05, 2018
Precision vs. Personalized Medicine Part I: Precision Approach
So often the phrases "Precision Medicine" and "Personalized Medicine" are used interchangeably. Are they really synonyms? Part I looks at Precision Medicine...
JUN 20, 2018
JUN 20, 2018
Peruvian Plant's Unique Anti-Tumor Biological Mechanism Discovered
Plagiochiline A is a molecule that exhibits antiproliferative properties and is cytotoxic. New research outlines the unique biological mechanism valued as possible cancer therapy target....
JUL 09, 2018
Cell & Molecular Biology
JUL 09, 2018
Scientists Found a New Way to Treat Lung Cancer
Small cell lung cancer is an aggressive type that can be fatal; there were few treatments for the disease. That may have changed....
JUL 10, 2018
JUL 10, 2018
Risk Allele Variant SNP at 14q11.2 Linked to ALL
Researchers utilized genome-wide association studies to identify a variant SNP within a gene at 14q11.2 which is linked to ALL....
OCT 02, 2018
Health & Medicine
OCT 02, 2018
Many Patients Are Unaware of Increased Cancer Risk
Just as recently as a few decades ago, many common health screenings were not readily available. Mammography, for breast cancer detection, wasn't ...
OCT 14, 2018
OCT 14, 2018
The Stem of Cancer
Scientists reveal a pathway involved in cancer cell ability to act as stem cells...
Loading Comments...